Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.70 +0.16 (+0.65%)
Official Closing Price Updated: 4:10 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Exposures Political
What's Driving the Market Sentiment Around Pfizer?
Via Benzinga
3 Things You Need to Know If You Buy Pfizer Today
Via The Motley Fool
Market Monitor February 24th
Wall Street Slumps Amid Consumer Worries and New Virus Concerns from China 
Via Chartmill
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold Forever
Via The Motley Fool
3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
Via The Motley Fool
These S&P500 stocks are the most active in today's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Friday. Discover the stocks that are generating the highest... 
Via Chartmill
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma. 
Via Benzinga
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi. 
Via Benzinga
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Via The Motley Fool
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Curious about the most active S&P500 stocks in today's session?
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Which S&P500 stocks are the most active on Wednesday?
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
Exposures Political Tariff
Rule Breaker Investing Stock Stories, Vol. 10: Frosty Campfire, Fiery Stocks
Every stock tells a story; it takes humans to find the meaning in it. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Love, Money, and Stocks
Via The Motley Fool
Which S&P500 stocks are the most active on Tuesday?
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest... 
Via Chartmill
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Exposures Political
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health. 
Via Benzinga
Topics ETFs
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.